Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.

Autor:	Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.; Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy. paolo_tarantino@dfci.harvard.edu., Gupta H; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Hughes ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Files J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strauss S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kirkner G; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Feeney AM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li Y; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro AC; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Barroso-Sousa R; Dasa Institute for Education and Research (IEPD), Brasilia, Brazil.; Dasa Oncology/Hospital Brasilia, Brasilia, Brazil., Bychkovsky BL; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA., DiLascio S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sholl L; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., MacConaill L; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lindeman N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Weill Cornell Medicine, New York, NY, USA., Johnson BE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Meyerson M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Jeselsohn R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Qiu X; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Long H; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Winer EP; Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA., Dillon D; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Curigliano G; Division of Early Drug Development, European Institute of Oncology IRCCS, Milano, Italy., Cherniack AD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	Nature communications [Nat Commun] 2023 Nov 18; Vol. 14 (1), pp. 7496. Date of Electronic Publication: 2023 Nov 18.
DOI:	10.1038/s41467-023-43324-w
Abstrakt:	The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast cancer undergoing next-generation sequencing from 7/2013-12/2020, we compare results between HER2-low (n = 487, 47%) and HER2-0 tumors (n = 552, 53%). A significantly higher number of ERBB2 alleles (median copy count: 2.05) are observed among HER2-low tumors compared to HER2-0 (median copy count: 1.79; P = 2.36e-6), with HER2-0 tumors harboring a higher rate of ERBB2 hemideletions (31.1% vs. 14.5%). No other genomic alteration reaches significance after accounting for multiple hypothesis testing, and no significant differences in tumor mutational burden are observed between HER2-low and HER2-0 tumors (median: 7.26 mutations/megabase vs. 7.60 mutations/megabase, p = 0.24). Here, we show that the genomic landscape of HER2-low and HER2-0 tumors does not differ significantly, apart from a higher ERBB2 copy count among HER2-low tumors, and a higher rate of ERBB2 hemideletions in HER2-0 tumors. (© 2023. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink